MedTrace Logo

Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy

NCT03294109 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2022-01-10

Study results available
· View outcomes & findings →

Summary

A blinded randomized control trial in living kidney donors. The study group will receive a liposomal bupivacaine Trans Quadratus Lumborum (TQL) block after the induction of general anesthesia. The following study variables will be collected postoperatively following arrival in the post-anesthesia care unit. Current and maximum intensity pain scores will be documented by nurses in Electronic Health Record (EHR). Total opiate dose consumed every 24 hours will be collected from the EHR and pain diary after discharge. Patient satisfaction will be evaluated using the Revised American Pain Society Patient Outcome Questionnaire (APS-POQ-R) 24 hours' post-procedure. Incidence of nausea will be extracted from nursing notes.

Conditions

  • Pain, Postoperative
  • Analgesics, Opioid
  • Analgesics, Non-Narcotic
  • Physiological Effects of Drugs
  • Peripheral Nervous System Agents
  • Patient Satisfaction
  • Return to Work
  • Activity, Sexual

Interventions

DRUG

Abdominal wall block with liposomal bupivicaine

Abdominal wall block with liposomal bupivicaine

Sponsors & Collaborators

Principal Investigators

  • Siamak Rahman, MD · University of California, Los Angeles

  • Hans a Gritsch, MD · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2020-06-24
Completion
2020-06-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03294109 on ClinicalTrials.gov